Eton Pharmaceuticals shares fall 3.09% intraday as Relief Therapeutics announces a business combination with NeuroX.

Eton Pharmaceuticals, Inc. declined 3.09% in intraday trading. The drop in stock price may be attributed to the proposed business combination between Relief Therapeutics and NeuroX, which could potentially divert investor attention and resources away from Eton Pharmaceuticals, Inc. The transaction, expected to close in Q4 2025, aims to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company.